ClinicalTrials.gg
RecruitingNCT07681076Updated Oct 15, 2026

Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers

A Phase 4 interventional study of KarXT and Trimethobenzamide in Healthy Volunteers, sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company. Recruiting at 4 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company (part of Bristol-Myers Squibb) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 15, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 290 studies in Nausea with a site in United States — 29 open to participants now, 32 under way, 8 of them phase 3. Nausea · United States.

Planned enrollment
66th of 260
180 · median 86
Started
2026
with 7 others
Phase 4
38 of 290
3 open now
Primary completion
2026-11
later than 6 of 31 live
Registered
286th of 290
by date

Among the 290 studies in Nausea with a site in United States, this one is the 66th largest by planned enrollment of the 260 interventional ones that give a count, is one of 8 that started in 2026, is one of 38 in phase 4, reaches primary completion later than 6 of the 31 other live ones, and was the 286th registered.

Nausea

644 studies on the registry are indexed under Nausea; 85 are open to participants now.

Browse Nausea studies →

Open to participants now

29 of the 290 studies in Nausea with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Nausea studies recruiting now, 21 (41%) set no upper age limit and 19 (37%) stop at 75 or younger; 10 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 290 studies in Nausea with a site in United States, or all of them as a file.
02

Study summary

This study looks at how to reduce nausea and vomiting in people taking KarXT which is used to treat mental health conditions like schizophrenia. KarXT can cause stomach-related side effects, especially in the first couple of weeks. In this study, healthy volunteers will take KarXT along with anti-nausea medication, either regularly (to prevent symptoms) or as needed.

The goal is to see how well these strategies help reduce nausea and vomiting and how safe the combination is. The results will help doctors better manage side effects and make treatment more comfortable for patients starting KarXT.

03

Conditions studied

  • Healthy Volunteers

Browse trials for

Keywords

  • BMS-986510
  • KarXT
  • Xanomeline/Trospium
  • Antiemetics
  • Nausea
  • Vomiting
  • Gastrointestinal side effects
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be healthy male and female participants as determined by no deviation from normal in medical history, physical examination, 12-lead , VS, and clinical laboratory determinations.
  • Participants must be willing and able to be confined to an inpatient setting for a 3-week duration, follow instructions, and comply with the protocol requirements.
  • Participants must have ≥ 18 and ≤ 40 kg/m2.
  • Individuals of (IOCBP) must be willing and able to adhere to the guidelines.

Exclusion criteria

Exclusion Criteria:

  • Participants must not have history or presence of cardiovascular (eg, untreated or unstable hypertension, clinically significant tachycardia), pulmonary, renal, hematologic, gastrointestinal ([GI] eg, obstructive disorders [including conditions that may decrease GI motility, such as ulcerative colitis, intestinal atony, and myasthenia gravis], active biliary disease [including symptomatic gallstones]), endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the participant or the validity of the study results.
  • Participants must not have history of moderate to severe alcohol use disorder or a substance (other than nicotine or caffeine) use disorder within the past 12 months or a positive urine drug screen (UDS) for a substance other than cannabis at screening or baseline.
  • Participants must not have history or high risk of urinary retention, gastric retention, or narrow-angle glaucoma.
  • Participants must not have active biliary disease (eg, symptomatic gallstones). Participants with other biliary histories are eligible and should be discussed with the medical monitor.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Arm 1

    Drug: KarXT · Drug: Trimethobenzamide

  • Experimental
    Arm 2

    Drug: KarXT · Drug: Ondansetron

  • Experimental
    Arm 3

    Drug: KarXT · Drug: Meclizine

  • Experimental
    Arm 4

    Drug: KarXT

Interventions

  • DrugKarXT

    Drug pages: Xanomeline · Trospium

    Specified dose on specified days

    Also known as: Xanomeline/Trospium Chloride, BMS-986510

  • DrugTrimethobenzamide

    Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Number of participants with Treatment Emergent Adverse Events (TEAEs)

    Nausea and vomiting

    Time frame: Up to Day 21

Secondary outcomes

  1. Number of participants with TEAEs

    Nausea and vomiting

    Time frame: Up to Day 14

  2. Time to first onset of nausea and vomiting

    Time frame: Up to Day 21

  3. Time to resolution of first episode of nausea or vomiting

    Time frame: Up to Day 21

  4. Number of participants with TEAEs

    Time frame: Up to Day 28

  5. Number of participants with serious TEAEs

    Time frame: Up to Day 28

  6. Number of participants with Adverse Events of Special Interests (AESIs)

    Time frame: Up to Day 28

  7. Number of participants with TEAEs leading to discontinuation

    Time frame: Up to Day 28

  8. Number of participants with clinically abnormal Vital signs

    Time frame: Up to Day 28

  9. Number of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to Day 21

07

Study locations

4 of 4 sites recruiting
  • Collaborative Neuroscience Network - Los Alamitos- CenExel - PPDS
    Los Alamitos, California 90720, United States
    Recruiting
    • David Walling, Site 0004 · Contact714-799-7799
  • CenExel RCA - Hollywood
    Hollywood, Florida 33024-2639, United States
    Recruiting
    • Edwin Gomez, Site 0002 · Contact954-604-3900
  • Atlanta Center for Medical Research - CenExel ACMR - PPDS
    Atlanta, Georgia 30331, United States
    Recruiting
    • Elyssa Barron, Site 0001 · Contact404-881-5800
  • iResearch Atlanta - CenExel - PPDS
    Decatur, Georgia 30030, United States
    Recruiting
    • Kimball Johnson, Site 0003 · Contact404-537-1281
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Nov 2026, 2 months after the start.

Of 27 phase 4 interventional studies under Nausea, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's planned 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2026
First posted
Jul 2, 2026
StartActual
Sep 3, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
225→180
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Enrollment 225→180
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07681076
Responsible party
Sponsor
First posted
Jul 2, 2026
Start date
Sep 3, 2026
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Oct 15, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Xanomeline · Trospium

Start the discussion